Advertisement Scient'x launches Tribeca Cage system - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Scient’x launches Tribeca Cage system

Scient'x, a manufacturer of spinal implant technologies, has launched the Tribeca Cage system which allows the surgeon to utilize a unilateral transforaminal approach to interbody cage insertion to minimize dural exposure.

The Scient’x Tribeca cage implants are indicated for use with autogenous bone graft as an intervertebral body fusion device at either one or two contiguous levels in the lumbosacral spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to grade I spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies.

According to the company, the Tribeca Cage is to be used in skeletally mature patients who have had six months of non-operative care. The Tribeca Cage is implanted using an anterior approach or posterior approach and is intended to be used single or in pairs with Isobar 6.2mm hemispherical screws with offset clamps and 5.5mm rods.

Michael Huggins, CEO of Scient’x, said: “I am excited about this product launch. The Tribeca Cage System offers innovative features and surgeon-friendly instrumentation, and will be a key addition to the Scient’x product portfolio.”